Evidence map›Paper›PMID 41530116›Full record

ArticleCell death & disease2026

Correction: UHRF1-mediated epigenetic reprogramming regulates glycolysis to promote progression of B-cell acute lymphoblastic leukemia.

Yan Huang, Luting Luo, Yangqi Xu, Jiazheng Li, Zhengjun Wu, Chenxing Zhao, Jingjing Wen, Peifang Jiang, Haojie Zhu, Lingyan Wang and 3 more

Abstract readPublished Erratum
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Yan Huang *Fujian Medical University Union Hospital, Fuzhou, Fujian, PR China.
Luting Luo *Fujian Medical University Union Hospital, Fuzhou, Fujian, PR China.
Yangqi XuFujian Medical University Union Hospital, Fuzhou, Fujian, PR China.
Jiazheng LiZhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, PR China.
Zhengjun WuFujian Medical University Union Hospital, Fuzhou, Fujian, PR China.
Chenxing ZhaoDepartment of Immunology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, PR China.
Jingjing WenDepartment of Lymphoma, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, Fujian, PR China.
Peifang JiangZhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, PR China.
Haojie ZhuThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, PR China.
Lingyan WangFujian Medical University Union Hospital, Fuzhou, Fujian, PR China.
Yanxin ChenFujian Medical University Union Hospital, Fuzhou, Fujian, PR China. chenyx158@163.com.ORCID http://orcid.org/0000-0001-5230-571X
Ting YangThe Second Department of Hematology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, PR China. yang.hopeting@gmail.com.ORCID http://orcid.org/0000-0001-6604-8937
Jianda HuFujian Medical University Union Hospital, Fuzhou, Fujian, PR China. drjiandahu@163.com.ORCID http://orcid.org/0000-0002-4438-2544

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41530116
PMCPMC12800260

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.